Gilead Sciences has agreed to break its patent a year earlier than anticipated. Gilead Sciences—the pharmaceutical company that holds a patent on the highly effective HIV prevention drug Trvuada, or PrEP—is releasing its hold on the drug earlier than expected, meaning a generic version of Truvada will be available as early…